Cargando…
Drug Resistance in Glioblastoma: The Two Faces of Oxidative Stress
Glioblastomas (GBM) are the most common primary brain tumor with a median survival of 15 months. A population of cells with stem cell properties (glioblastoma stem cells, GSCs) drives the initiation and progression of GBM and is localized in specialized microenvironments which support their behavior...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7873048/ https://www.ncbi.nlm.nih.gov/pubmed/33585565 http://dx.doi.org/10.3389/fmolb.2020.620677 |
_version_ | 1783649311940149248 |
---|---|
author | Olivier, Christophe Oliver, Lisa Lalier, Lisenn Vallette, François M. |
author_facet | Olivier, Christophe Oliver, Lisa Lalier, Lisenn Vallette, François M. |
author_sort | Olivier, Christophe |
collection | PubMed |
description | Glioblastomas (GBM) are the most common primary brain tumor with a median survival of 15 months. A population of cells with stem cell properties (glioblastoma stem cells, GSCs) drives the initiation and progression of GBM and is localized in specialized microenvironments which support their behavior. GBM are characterized as extremely resistant to therapy, resulting in tumor recurrence. Reactive oxygen species (ROS) control the cellular stability by influencing different signaling pathways. Normally, redox systems prevent cell oxidative damage; however, in gliomagenesis, the cellular redox mechanisms are highly impaired. Herein we review the dual nature of the redox status in drug resistance. ROS generation in tumor cells affects the cell cycle and is involved in tumor progression and drug resistance in GBM. However, excess ROS production has been found to induce cell death programs such as apoptosis and autophagy. Since GBM cells have a high metabolic rate and produce high levels of ROS, metabolic adaptation in these cells plays an essential role in resistance to oxidative stress-induced cell death. Finally, the microenvironment with the stromal components participates in the enhancement of the oxidative stress to promote tumor progression and drug resistance. |
format | Online Article Text |
id | pubmed-7873048 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-78730482021-02-11 Drug Resistance in Glioblastoma: The Two Faces of Oxidative Stress Olivier, Christophe Oliver, Lisa Lalier, Lisenn Vallette, François M. Front Mol Biosci Molecular Biosciences Glioblastomas (GBM) are the most common primary brain tumor with a median survival of 15 months. A population of cells with stem cell properties (glioblastoma stem cells, GSCs) drives the initiation and progression of GBM and is localized in specialized microenvironments which support their behavior. GBM are characterized as extremely resistant to therapy, resulting in tumor recurrence. Reactive oxygen species (ROS) control the cellular stability by influencing different signaling pathways. Normally, redox systems prevent cell oxidative damage; however, in gliomagenesis, the cellular redox mechanisms are highly impaired. Herein we review the dual nature of the redox status in drug resistance. ROS generation in tumor cells affects the cell cycle and is involved in tumor progression and drug resistance in GBM. However, excess ROS production has been found to induce cell death programs such as apoptosis and autophagy. Since GBM cells have a high metabolic rate and produce high levels of ROS, metabolic adaptation in these cells plays an essential role in resistance to oxidative stress-induced cell death. Finally, the microenvironment with the stromal components participates in the enhancement of the oxidative stress to promote tumor progression and drug resistance. Frontiers Media S.A. 2021-01-27 /pmc/articles/PMC7873048/ /pubmed/33585565 http://dx.doi.org/10.3389/fmolb.2020.620677 Text en Copyright © 2021 Olivier, Oliver, Lalier and Vallette. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Molecular Biosciences Olivier, Christophe Oliver, Lisa Lalier, Lisenn Vallette, François M. Drug Resistance in Glioblastoma: The Two Faces of Oxidative Stress |
title | Drug Resistance in Glioblastoma: The Two Faces of Oxidative Stress |
title_full | Drug Resistance in Glioblastoma: The Two Faces of Oxidative Stress |
title_fullStr | Drug Resistance in Glioblastoma: The Two Faces of Oxidative Stress |
title_full_unstemmed | Drug Resistance in Glioblastoma: The Two Faces of Oxidative Stress |
title_short | Drug Resistance in Glioblastoma: The Two Faces of Oxidative Stress |
title_sort | drug resistance in glioblastoma: the two faces of oxidative stress |
topic | Molecular Biosciences |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7873048/ https://www.ncbi.nlm.nih.gov/pubmed/33585565 http://dx.doi.org/10.3389/fmolb.2020.620677 |
work_keys_str_mv | AT olivierchristophe drugresistanceinglioblastomathetwofacesofoxidativestress AT oliverlisa drugresistanceinglioblastomathetwofacesofoxidativestress AT lalierlisenn drugresistanceinglioblastomathetwofacesofoxidativestress AT vallettefrancoism drugresistanceinglioblastomathetwofacesofoxidativestress |